Table 2.
Ocular manifestations and clinical outcomes of 37 patients with CMVR.
| Characteristic | According to patients (n = 37) | According to eyes (n = 55) |
|---|---|---|
| Gender | ||
| Female | 12 (32.4%) | |
| Male | 25 (67.6%) | |
| Diagnosis | ||
| SAA | 27 (72.9%) | |
| vSAA | 10 (27.1%) | |
| Involved eye | ||
| OD | 12 (32.4%) | 30 (54.5%) |
| OS | 7 (18.9%) | 25 (45.5%) |
| OU | 18 (18.6%) | |
| *Size of retinal lesions | ||
| < 10% | 24 (43.6%) | |
| 10% to 50% | 22 (40.0%) | |
| > 50% | 9 (16.4%) | |
| Treatment of CMVR | ||
| Combined IVTG and systemic administration of antiviral drugs | 28 (75.7%) | 40 (72.8%) |
| IVTG only | 2 (5.4%) | 3 (5.4%) |
| CMV-CTL immunotherapy targeting drug-resistant CMVR | 2 (5.4%) | 3 (5.4%) |
| No treatment | 5 (13.5%) | 9 (16.4%) |
| ∧Visual prognosis | ||
| Improvement | 27 (49.1%) | |
| Stabilization | 17 (30.9%) | |
| Deterioration | 11 (20.0%) | |
| Follow up period-mth | 18.2 (5.9–33.8) | |
| #One-year mortality | 6 (16.2%) |
CMVR, cytomegalovirus retinitis; SAA, severe aplastic anemia; vSAA, very severe aplastic anemia; OD, right eye; OS, left eye; OU, both eyes; IVTG, intravitreal injection of ganciclovir; CMV-CTL, CMV specific cytotoxic T lymphocytes. *The sizes of retinal lesions were classified as involving < 10%, 10% to 50% and > 50% of the total retinal area based on the fundus photograph. ∧The visual outcome was defined as improvement, stabilization and deterioration. Improvement was defined if best-corrected visual acuity was increased two or more lines. Stabilization was defined if the changed best-corrected visual acuity was less than two lines. Deterioration was defined as a decreased best-corrected visual acuity more than two lines. A Snellen chart was used to record the visual acuity data. #The causes of death of the six patients were CMV pneumonia (2 cases), Epstein-Barr virus-related post-transplant lymphoproliferative disease (1 case), septic shock (1 case), graft rejection (1 case) and commit suicide (1 case).